Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M110729200 on January 30, 2002

J. Biol. Chem., Vol. 277, Issue 15, 12689-12696, April 12, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/15/12689    most recent
M110729200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ni, H.
Right arrow Articles by Weissman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ni, H.
Right arrow Articles by Weissman, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-alpha Secretion and Signaling through a Nucleotide Receptor*

Houping NiDagger , John CapodiciDagger , Georgetta CannonDagger , Didier Communi§, Jean-Marie Boeynaems§, Katalin Karikó, and Drew WeissmanDagger ||

From the Divisions of Dagger  Infectious Diseases and  Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 and the § Institute of Interdisciplinary Research and Department of Medical Chemistry, School of Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels 1070, Belgium

Received for publication, November 8, 2001, and in revised form, January 9, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We previously demonstrated that dendritic cell (DC) pulsing with antigen-encoded mRNA resulted in the loading of both major histocompatibility complex class I and II antigen presentation pathways and the delivery of an activation signal. Coculture of mRNA-pulsed DC with T cells led to the induction of a potent primary immune response. DC, in addition to recognizing foreign antigens through pattern recognition receptors, also must respond to altered self, transformed, or intracellularly infected cells. This occurs through cell surface receptors that recognize products of inflammation and cell death. In this report, we characterize two signaling pathways utilized by extracellular mRNA to activate DC. In addition, a novel ligand, poly(A), is identified that mediates signaling through a receptor that can be inhibited by pertussis toxin and suramin and can be desensitized by ATP and ADP, suggesting a P2Y type nucleotide receptor. The role of this signaling activity in vaccine design and the potential effect of mRNA released by damaged cells in the induction of immune responsiveness is discussed.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Dendritic cells (DC)1 are the sentinel cells of the adaptive immune system and function in the induction of primary and memory T cell immune responses (1, 2). They mainly populate tissues that interface with the environment and acquire antigens through high level constitutive macropinocytosis and endocytosis (3). Immature tissue DC sense invading organisms by recognizing evolutionarily conserved structures, known as pathogen-associated molecular patterns, contained within microbial lipids, carbohydrates, and nucleic acid. This pattern recognition occurs through a set of germ-line encoded receptors, which are exemplified by the Toll-like receptor (TLR) family (4-6). Immature DC, upon receiving an activation signal, undergo phenotypical and functional changes, including: 1) decreased antigen acquisition with a coordinated increase in presentation of MHC-peptide complexes on the cell surface; 2) increased stability of MHC class II-peptide complexes; 3) increased expression of surface molecules that aid and promote T cell activation (7); 4) a changed pattern of release of chemokines and cytokines leading to attraction of T cells, promotion of T cell activation, and direction of their ultimate phenotype (Th0, Th1, Th2, or T regulatory (Treg)) (5, 8, 9); and 5) a shift in the repertoire of chemokine receptor expression that allows and directs DC migration to lymphoid organs (10, 11).

Identified categories of DC activators include: 1) conserved constituents of bacteria (lipopolysaccharide (LPS), cell wall lipoproteins, flagellar proteins, and DNA), 2) host cell-derived molecules released during cell injury and death (proinflammatory cytokines and nucleotides), 3) intermediates of viral replication (double-stranded RNA (dsRNA)) (12), and 4) molecules on activated CD4+ T cells (CD40 ligand (CD40L)). The signaling by each DC activator leads to the transformation of a DC from antigen acquisition to antigen presentation but produces a DC that differs in the type of immune response it induces (13). DCs treated with TNF-alpha , a pleiotropic stimulus of DC activation, and prostaglandin E produce a low level of IL-12 and induce a mixed population of Th0 and Th1 T cells. DCs exposed to dsRNA secrete high levels of IL-12 and IFN-alpha leading to a strong Th1 response. DCs exposed to apoptotic cells or malaria-infected red blood cells do not secrete IL-12 but produce IL-10 (14, 15) leading to the induction of Treg cells (16).

Nucleotide receptors are comprised of two families, a metabotropic family (P2Y) that belong to the 7-transmembrane, G-protein coupled receptor (GPCR) superfamily, and a pore-forming, cation-selective family (P2X). Human DCs express mRNA for P2Y1, -2, -4, -6, -11 and P2X1, -2, -4, -5, -7 nucleotide receptors (17). Signaling through both families by selected nucleotides induces different aspects of DC activation. ATP, which can be released by damaged cells and has been demonstrated to synergize with TNF-alpha in the activation of DCs (18, 19), acts through P2Y11 receptor signaling. This signaling pathway leads to the generation of cAMP (19). The P2X7 receptor is important in cytokine secretion in human DC (20) and antigen presentation in murine DC (21). In addition to DC activation, it has also been observed that signaling through nucleotide receptors by ATP leads to DC apoptosis (22) and aberrant DC activation. DC pretreated with low, non-toxic doses of ATP, produced lower amounts of IL-1alpha , IL-1beta , TNF-alpha , IL-6, and IL-12 after subsequent stimulation with LPS or CD40L (23).

The targeting of DC for antigen delivery in vivo and in vitro represents an important approach in vaccine research. The first step in immune responsiveness induced by vaccines is the delivery of antigen in a form that the DC can acquire, process, and present to CD4+ T, CD8+ T, and/or B cells. With this delivery of antigen, the vaccine also must deliver an activation signal to the DC. This is often done by the inclusion of adjuvants, such as mycobacterium to complete Freund's adjuvant, or with components of the antigen delivery system, such as CpG motifs in DNA vaccines (reviewed in Ref. 24). We previously reported that pulsing DC with mRNA encoding antigen led to loading of both CD4+ and CD8+ T cell antigen presentation pathways, delivery of an activation signal to DC, and the induction of potent antigen-specific T cell activation (25). In this report, we determined the mechanisms whereby mRNA activates DC.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In Vitro RNA Transcription-- Transcription was performed on Gag- and luciferase-encoding plasmid templates linearized downstream from a stretch of dA50 using the T7 message machine kit (Ambion, Austin, TX) as described previously (25). Purification of the transcripts was performed by DNase I digestion followed by LiCl precipitation and 70% EtOH washing. Additional poly(A) tail was added to the transcripts with yeast poly(A) polymerase (Amersham Biosciences, Inc., Piscataway, NJ), and the mRNA was again purified. All Gag- or luciferase-encoding mRNA contained a poly(A) tail unless otherwise noted. Assays for LPS in RNA preparations using the Lumilus Amebocyte Lysate gel clot assay were negative with a sensitivity of 3 pg/ml (University of Pennsylvania, Department of Genetics, Cell Center Service Facility). The quality of each batch of mRNA was tested by agarose gel electrophoresis for degradation. Samples were stored in siliconized tubes at -20 °C until use.

Cell Culture-- HL60, U937, and 293T cells (ATCC, Rockville, MD) and P2Y11 nucleotide receptor stably transfected Chinese hamster ovary and 1231N1 cells (26) were propagated in Dulbecco's modified Eagle's medium supplemented with glutamine (Invitrogen, Rockville, MD) and 10% FCS (HyClone, Ogden, UT). Leukapheresis samples were obtained from HIV-uninfected volunteers through an institutional review board-approved protocol. Peripheral blood mononuclear cells (PBMC) were purified by Ficoll-Hypaque density gradient purification. PBMC were cryopreserved in RPMI 1640 (Invitrogen) with 50% FCS and 10% Me2SO (Sigma Chemical Co., St. Louis, MO). DCs were produced as described previously with minor modifications (25). Monocytes were obtained by the RosetteSep method (Stem Cell Technologies, Vancouver, BC, Canada) from leukapheresis samples (containing red blood cells) as described by the manufacturer. Monocytes were cultured in AIM V serum-free medium (Invitrogen) supplemented with granulocyte macrophage/colony-stimulating factor (50 ng/ml) and IL-4 (100 ng/ml) (R&D Systems, Minneapolis, MN). Fresh medium containing cytokines was added on days 2 and 5. The resulting immature DCs were used between 6 and 9 days after initial culture of monocytes.

DCs were treated with TNF-alpha (1 ng/ml) (R&D Systems) + PGE3 (500 nM) (Cayman Chemical Co., Ann Arbor, MI), LPS (1.0-10 µg/ml) (Sigma), CD40L trimer (a kind gift of Elaine Thomas, Immunex, Seattle, WA), poly(A) and poly(U) single-stranded (ss) RNA, poly(I)·poly(C) dsRNA (20 µg/ml) (Sigma), Gag- or luciferase-encoding mRNA (0.22 µg/50 µl) complexed with Lipofectin (Invitrogen) (27) or Lipofectin without nucleic acid. Higher concentrations of LPS were required for DC maturation, because no serum was present in the cultures, thus LPS bound and activated DC in the absence of serum-derived LPS-binding protein. Similar activation profiles were observed for LPS when exogenous serum was added.

293T cells were transiently transfected with a cytomegalovirus-driven P2Y4 expression plasmid (28) complexed to Lipofectin in the same manner as RNA. After 24 h, cells, or control transfected 293T cells, were analyzed for the ability to flux Ca2+ in response to poly(A) or UTP (Sigma).

Ca2+ Signal Fluorescence Determinations-- Ca2+ flux was determined by measuring fluorescence spectral changes of Fura-2 (Molecular Probes, Eugene, OR). The excitation wavelengths were 340 and 380 nm, and the measured emission wavelength was 510 nm. All experiments were performed at 37 °C using a Photon Technology International fluorescence spectrophotometer (London, Ontario, Canada) equipped with a magnetic stirrer. Cells were loaded with Fura-2AM for 1 h at 37 °C in RPMI 10% FCS followed by washing. One and one-half million Fura-2 loaded cells in 1 ml of Hanks' balanced salt solution with Ca2+ and Mg2+ (Invitrogen) were added to a cuvette and analyzed to establish a baseline followed by addition of stimuli. Data are presented as the ratio of emissions at 510 nm. Certain cells were treated with pertussis toxin (30 µg/ml) (Sigma) 5 h before signaling or suramin (30 µM) or EGTA (200 µM) (Sigma) 10 min before signaling. Cells were stimulated with ATP (1-100 µM), 2MeSATP (1-5 µM), ADP (5-100 µM), UTP (20-100 µM), poly(A) (1-67 µM AMP equivalents), poly(U), poly(C), poly(G), poly(A,C), poly(A,G), poly(A,U) (67 µM AMP equivalents) (Sigma), Gag-encoding mRNA with or without a poly(A) tail (30 µg added to 1.5 ml cells) or RANTES (BD PharMingen, San Jose, CA) (33 ng/ml), and the calcium flux was monitored for up to 600 s at 1-s intervals. In certain experiments, ATP and 2MeSATP (1 mM) were treated for 90 min with creatine phosphokinase (CPK) (20 units/ml) and creatine phosphate (CP) (10 mM) (Sigma) to convert contaminating ADP and 2MeSADP to ATP and 2MeSATP, respectively (29). Desensitization was measured by adding the second or third stimulus when the calcium flux subsided and the baseline was re-established.

Analysis of DC Maturation and T Cell Activation by DC-- DC were stained for the following markers with directly conjugated antibodies: CD83-phycoerythrin (PE) or fluorescein isothiocyanate (FITC), CD80-PE (Research Diagnostics Inc., Flanders, NJ), HLA-DR-FITC, HLA-A, B,C-FITC, CD25-FITC, CCR5-FITC, CXCR4-PE, CD86-Cy-Chrome, CCR6-PE (BD PharMingen, San Diego, CA) and analyzed on a FACSCalibur (BD PharMingen) flow cytometer. Endocytosis/macropinocytosis was measured by incubating DCs with FITC-labeled bovine serum albumin (Sigma) for 1 h at 37 °C followed by washing and analysis.

For studies of T cell activation, immature or activated DC were washed to remove the activating agent and cultured with autologous CD4+ T cells purified by negative selection (Human CD4+ T Cell Enrichment Column, R&D Systems) from cryopreserved PBMC at a ratio of 1 DC to 10 T cells and staphylococcal toxic shock surperantigen (Sigma) (0.01 ng/ml). One hour later, brefeldin A (20 µg/ml) (Sigma) was added. Five hours later, cells were stained with CD4-APC (BD PharMingen), permeabilized, and stained with CD69-Peridinin chlorophyll, IFN-gamma -FITC, and IL-4-PE (BD PharMingen) as described previously (30) and analyzed on a FACSCalibur flow cytometer, 500,000 events per sample.

ELISA Assays for cAMP and Cytokines-- 3-Isobutyl-1-methylxanthine (5 µM)-treated (30 min) DCs were activated for 30 min and lysed for cAMP quantitation. cAMP level was measured by competitive chemiluminescence assay (Applied Biosystems, Foster City, CA) as per manufacturer's instructions. Supernatants of activated DC were collected at 48 h for cytokine measurement. IL-12 (p70) (BD PharMingen), TNF-alpha , IFN-alpha , and IL-8 (BIOSOURCE International, Camarillo, CA) were measured in supernatants by sandwich ELISA. Cultures were performed in duplicate and measured in duplicate.

Statistical Analysis-- Student's t tests were performed using Microsoft Excel software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

mRNA Induces DC Activation-- DC activation is induced by classes of stimuli through specific receptors (TLR, TNF family, nucleotide, prostaglandin) and signaling cascades. Although each of these classes of agents induces activation and maturation of DC, the function of the resulting DC regarding the type of immune response induced differs. We previously demonstrated that HIV Gag-encoding mRNA activates DC as measured by expression of the DC maturation marker CD83 and antigen-specific T cell activation (25). To better define the phenotype of mRNA activated DC, we studied the following markers of DC activation: 1) MHC classes I and II and costimulatory (CD80, CD86) molecules necessary for T cell activation, 2) chemokine receptors (CCR5, CCR6, CXCR4) that traffic DC to peripheral tissues and lymphoid organs, 3) functional uptake of extracellular antigen, and 4) cytokines (IL-12, IL-8, IFN-alpha , TNF-alpha ) released by DC that regulate and shape the resulting T cell response. mRNA in comparison to the standard DC activation agents, LPS, TNF-alpha  + PGE3, dsRNA, and CD40L, demonstrated the greatest increase in surface proteins associated with T cell activation, CD80, CD86, and MHC classes I and II, and lesser regulation of chemokine receptor expression (Fig. 1 and Table I). Both Gag- and luciferase-encoding mRNA-containing poly(A) tails were used, and no difference in activation of DC was observed. Poly(A) minimally increased CD83 and induced a smaller subset of markers of DC activation while poly(U) did not induce markers of DC activation (Fig. 1 and Table I).


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 1.   RNA activates DC as measured by the up-regulation of T cell activation molecules and modulation of chemokine receptors. Dotted lines, immature; thin solid lines, LPS (1.0 µg/ml) treated; and heavy solid lines, Gag-encoding mRNA pulsed DC were analyzed for expression of CD80, CD86, MHC classes I and II, CXCR4, and CCR5 after 24 h. Data presented are from one DC preparation and are representative of at least five preparations from at least five different donors.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Rank order change of DC activation markers by stimuli
The changes in DC activation markers induced by each stimuli after 24-48 h of treatment of immature DC were quantitated (mean fluorescence by flow cytometry for surface molecule expression and amount in supernatant by ELISA for cytokines) and rank-ordered with 1 being change compared to immature (no treatment). Rank order placement of each activator was determined if a statistically different result was observed in comparing at least five separate experiments between activators. An equal rank was given if no statistically significant difference was observed between activators.

The cytokines produced by activated DC during interactions with T cells determines, in part, the phenotype of the resulting T cell response. IL-12, IFN-alpha , TNF-alpha , and IL-8 are differentially produced in response to DC activation stimuli. IL-12 in humans acts on T cells to induce them to produce IFN-gamma (Th1 response). IFN-alpha acts on DCs to down-regulate IL-12 and increase IL-10 production (16). The lack of IL-12 and the production of IL-10 favor Th2 and Treg T cells. IL-8 acts to attract inflammatory cells and potentiates the local immune response (31). DC cytokine production induced by the different forms of activation demonstrated that mRNA led to moderate levels of IL-12 production compared with the very high levels observed with CD40L and the low amounts observed with TNF-alpha  + PGE3 stimulation (Fig. 2 and Table I). Gag encoding mRNA induced moderate levels of IFN-alpha and TNF-alpha , whereas poly(A) did not increase IFN-alpha or TNF-alpha production but induced IL-12 suggesting that poly(A) represented a subset of mRNA activation of DC.


View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2.   DC activation agents stimulate different patterns of cytokine secretion. Immature DC were treated with medium, Lipofectin, Lipofectin-complexed Gag-encoding mRNA, poly(A) and poly(U) ssRNA, LPS, poly(I)·poly(C) dsRNA, or CD40L for 48 h. Supernatants from duplicate cultures were analyzed in duplicate for TNF-alpha , IFN-alpha , IL-12 (p70) content by ELISA. Error bars represent the standard error of the mean of the four samples for each measurement. Data presented are from one DC preparation and are representative of six DC preparations from six different donors.

Activated DCs are superior to immature DC in inducing T cell activation. A system that measures the ability of DC maturation agents to increase DC-induced T cell activation was employed. Unactivated T cells were cocultured with immature or activated DC in the presence of suboptimal concentrations of superantigen for 6 h and then analyzed for the early activation marker CD69. mRNA mediated activation of DC resulted in the induction of CD69 on T cells at similar levels observed for other potent DC-activating agents (Fig. 3 and Table II). Studies examining the cytokines made by T cells activated by DC demonstrated that immature DC induced both IL-4- and IFN-gamma -secreting T cells (Fig. 4). This assay measured the percentage of cells induced to make IL-4 or IFN-gamma by DC stimulation and differs from other studies that polyclonally stimulate T cells after coculture with DCs, which determine the potential to produce a cytokine induced by the DC (12, 32). LPS induced predominantly IFN-gamma -producing T cells with a small population of IL-4 producing CD4+ T cells. Poly(I)·poly(C) activation of DC resulted in CD4+ T cells that produced almost entirely IFN-gamma but consistently had a lower percentage of total T cells making IFN-gamma compared with other stimuli. mRNA-treated DC activated CD4+ T cells to produce mainly IFN-gamma , similar to poly(I)·poly(C) and CD40L (Fig. 4 and data not shown).


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3.   DC activated by Gag-encoding mRNA are similar to poly(I)·poly(C)- and LPS-activated DC in the extent of expression of the early T cell activation marker CD69 in cocultured T cells. Immature DC treated for 24 h with medium, poly(I)·poly(C) (20 µg/ml), LPS (1 µg/ml), or Gag-encoding mRNA (4.4 µg/ml) were washed and cocultured with autologous CD4+ T cells and suboptimal concentrations of TSST-1 superantigen (0.01 ng/ml). Intracellular CD69 expression on CD4+ T cells was measured 6 h later by flow cytometry. Data presented are from one donor and are representative of two different donors.

                              
View this table:
[in this window]
[in a new window]
 
Table II
CD69 expression on CD4- T cells was determined after coculture with immature or activated DC
CD4+ T cells, cocultured with activated DC for 6 h in the presence of superantigen, were stained for CD4 and CD69 and analyzed using flow cytometry.


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 4.   mRNA activation of DC results in CD4+ T cells that produce IFN-gamma . DC activated with mRNA (4.4 µg/ml), LPS (1 µg/ml), or poly(I)·poly(C) (20 µg/ml) were cocultured with autologous CD4+ T cells, TSST-1 superantigen (0.01 ng/ml), and brefeldin A. After 6 h, cells were permeabilized, stained for IFN-gamma , IL-4, and CD69, and flow cytometrically analyzed. Presented histograms showing IFN-gamma versus IL-4 were gated on CD69+ cells. Although the percentage of cytokine-positive cells appears similar for each condition, as CD69+ cells were analyzed under each condition, the number of cytokine-positive CD4+ T cells in the immature DC coculture were approximately one quarter of that observed under other conditions (Fig. 3). Data from one subject are representative of two donors.

RNA Induces a Calcium Flux in DC-- We observed that poly(A) partially activated DC whereas mRNA fully induced DC maturation and that poly(A) did not whereas mRNA induced TNF-alpha secretion. It was recently demonstrated that ATP or TNF-alpha treatment of DC induced low level expression of the DC maturation marker CD83. The addition of both TNF-alpha and ATP resulted in a synergistic activation of DC (18). A similar synergy was also observed when TNF-alpha and poly(A) were used to activate DC (data not shown). ATP signals cells through nucleotide receptors that are divided into two families, one G-protein linked (P2Y) and the second through selective cation pore formation (P2X). Poly(A) at similar molar AMP equivalents as ATP stimulated a calcium flux in Fura-2-loaded DC (Fig. 5). Dose-response analysis demonstrated that 1.0 µM AMP equivalents of poly(A) could flux calcium in DC. In vitro transcribed mRNA encoding the HIV Gag protein and containing a 50-nucleotide or longer poly(A) tail also fluxed Ca2+ in DC, whereas mRNA lacking a poly(A) tail did not (Fig. 5). The P2X receptors flux extracellular calcium through plasma membrane pores, and their signaling is inhibited by removal of extracellular Ca2+ with EGTA. RNA signaling of DC was not inhibited by the absence of extracellular calcium, suggesting that it did not signal through P2X receptors (Fig. 5). These data suggested that poly(A) signaled through P2Y receptors present on DC whose ligands were previously identified as nucleotides.


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 5.   Poly(A) induces a Ca2+ flux in DC, which can be inhibited by pertussis toxin (PTX) and suramin. DC were preincubated with medium or pertussis toxin (30 µg/ml) for 5 h, loaded with Fura-2, treated with EGTA (200 µM) or suramin (30 µM) for 10 min, where indicated, and then stimulated with Gag-encoding mRNA with or without (noted with an asterisk) a poly(A) tail (30 µg/ml), ATP (100 µM), poly(A) (67 µM AMP equivalents), poly(U) (67 µM AMP equivalents), or RANTES (33 ng/ml) and followed for Fura-2 spectral changes induced by Ca2+ release. The ratio of emissions at 510 nm is given versus time. The same scale of ratio of light emission and time was used for each assay shown. Ca2+ fluxes presented were obtained from multiple samples of DC from different donors. Three to ten repetitions for each condition were performed.

P2Y nucleotide and many G-protein coupled 7-transmembrane receptors can be desensitized to subsequent signaling. This increase in EC50 required for subsequent signaling can be observed for the same or different ligands that share a receptor (33-35). DCs were sequentially stimulated with ATP, ADP, or UTP; poly(A); and RANTES (Fig. 6). UTP stimulation did not inhibit subsequent signaling by poly(A) or RANTES (Fig. 6). ATP, at low concentrations (1-5 µM), desensitized DC to poly(A), with little or no effect on subsequent RANTES signaling (Fig. 6). Higher concentrations of ATP were toxic as previously demonstrated (20) and observed in this assay by a loss of RANTES signaling. Two new P2Y receptors that are coupled to Gi and signal to ADP have recently been identified (29, 36). ADP completely desensitized DC to poly(A) (Fig. 6). ATP is rapidly degraded to ADP by ecto-nucleotidases on the surface of DC (17). To determine whether ATP or ADP derived from degraded ATP was responsible for desensitization, a non-hydrolyzable analog of ATP, 2MeSATP, was used after treatment with CPK and CP to convert contaminating 2MeSADP into 2MeSATP and desensitization was observed (Fig. 6). These data suggest that poly(A) likely signaled through a nucleotide receptor whose ligands included ATP and ADP and may be a member of a new family of ADP receptors more closely related to the UDP-glucose receptor (29, 36).


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 6.   Poly(A)-induced Ca2+ flux is blocked by a preliminary stimulation with ATP, 2MeSATP, or ADP but not UTP. Fura-2-loaded DC were sequentially stimulated with ATP (3 µM), UTP (20 µM), ADP (5 µM), and 2MeSATP (1 µM) treated with CPK and CP to convert contaminating 2MeSADP, poly(A) (67 µM AMP equivalents), and RANTES (33 ng/ml). The ratio of emissions at 510 nm versus time is presented. A low concentration of ATP was used to avoid toxic effects observed at higher ATP concentrations. Data are representative of three preparations of DC from three donors. Portions of data from two donors are shown.

GPCR desensitization is dependent on both the receptor and the ligand, and certain receptors are not desensitized by all of its ligands. An example of this is the lack of desensitization of CCR5 by MIP-1beta (37). Additional studies were performed to analyze each known P2Y receptor for poly(A) and mRNA signaling. A recent report demonstrated that ATP activated DC by signaling through the P2Y11 receptor. Signaling through this receptor, unlike other P2Y or P2X receptors expressed by DC, resulted in increased cAMP generation (19). To determine if RNA used this receptor, DCs were stimulated by poly(A) and cAMP was measured by competitive ELISA. Poly(A) did not increase cAMP with levels similar to unstimulated DC. ATP, which signals through P2Y11, increased the cAMP level 30-fold over baseline (Fig. 7). To confirm that RNA did not signal through P2Y11, cell lines (Chinese hamster ovary and 1231N1) stably expressing human P2Y11 (26) were loaded with Fura-2 and analyzed for Ca2+ flux. ATP but not poly(A) induced calcium fluxes, confirming that RNA did not signal through the P2Y11 nucleotide receptor. In addition, the observation that poly(A) induced IL-12 clearly distinguished it from ATP-induced DC maturation, which has been demonstrated to inhibit IL-12 secretion (19).


View larger version (6K):
[in this window]
[in a new window]
  		Fig. 7.   Poly(A) does not increase cAMP generation in DC. 3-Isobutyl-1-methylxanthine-treated DC were stimulated with medium, ATP (100 µM), poly(A) (67 µM AMP equivalents), and poly(U) (67 µM AMP equivalents), lysed 30 min later, and analyzed for cAMP content. Samples were performed in duplicate and analyzed in duplicate. Data from one subject's DC are representative three donors' DC.

We next sought to determine which P2Y nucleotide receptor signaled in response to poly(A) by utilizing the differential sensitivity to specific inhibitors of the members of this family. Pertussis toxin inhibits Gi-proteins and completely blocks beta-chemokine-mediated signaling through their respective receptors (38). P2Y2, -4, -12, and -13 but not P2Y1, -6, or -11 are sensitive to pertussis toxin-mediated inhibition when ligand concentration is low (39-41). Poly(A) and RANTES but not ATP or UTP signaling were blocked by pretreatment of DC with pertussis toxin (Fig. 5 and data not shown).

Suramin is a synthetic polysulfonated naphthylurea that blocks P2Y2 but not P2Y4 receptor signaling (40). When poly(A) was added to DCs that were preincubated with suramin, calcium flux was completely blocked, suggesting that P2Y2 was not responsible for RNA signaling (Fig. 5). Confirmatory investigation utilized cell lines (HL60 and U937) that expressed P2Y1 (HL60 only), P2Y2, and P2Y6 receptors and 293T cells transiently transfected with a P2Y4 expression plasmid. Both cell lines and P2Y4-transfected 293T cells fluxed calcium upon stimulation with ATP or UTP, respectively, but none responded to poly(A), suggesting that poly(A) signaled through a nucleotide receptor that could be desensitized with ADP and ATP and whose signaling was blocked by pertussis toxin and suramin. The distribution of the poly(A) signaling activity was limited because neither poly(A) nor mRNA signaled T, B, and monocytic cells derived from PBMC.

Our in vitro synthesized mRNA was prepared from nucleotide triphosphates and purified by LiCl precipitation and EtOH washing to remove free nucleotides. The lack of signaling of these RNA preparations on cell lines expressing P2Y1, -2, -4, -6, and -11 suggested that the RNA preparations did not contain contaminating nucleotides that were responsible for Ca2+ signaling. In addition, homopolymers other than poly(A) made by polynucleotide phosphorylase catalyzed polymerization of ADP, UDP, CDP, and/or GDP also did not signal DC, suggesting that the receptor likely recognized stretches of A in RNA and not contaminating ADP.

The data suggested that poly(A) represented a subset, moderate induction of markers of DC activation and IL-12 secretion but no TNF-alpha or IFN-alpha (Table I), of the DC maturation activity of mRNA. The ability of in vitro transcribed encoding mRNA to induce IFN-alpha and TNF-alpha suggested that part of the mRNA's DC maturation ability might be mediated by the formation of regions of dsRNA. This dsRNA would activate DC in a similar manner as poly(I)·poly(C), although it likely may not provide the same intensity of activation due to the lower levels of dsRNA content of the mRNA (12). It was also possible that the poly(A) signaling altered the dsRNA DC activation effect. This was supported by the differences in DC maturation markers induced by poly(I)·poly(C) and mRNA (Fig. 1 and Table I) and directly tested by demonstrating that adding poly(A) to poly(I)·poly(C) stimulation of DC altered the activation markers CD80 and CD86 such that it resembled mRNA activation (Fig. 8). The magnitude of change in the level of the activation markers, although relatively small, was reproduced in three separate experiments. The presented data normalized each experiment to equal untreated mean fluorescence for each activation marker and averaged the results of three experiments. Gag-encoding mRNA lacking a poly(A) tail, in addition to not fluxing Ca2+ in DC, induced fewer markers of DC maturation than mRNA containing a poly(A) tail suggesting that the additional signal delivered by poly(A) both increased DC activation and altered the phenotype of the resulting DC.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 8.   The addition of poly(A) to poly(I)·poly(C) alters the expression of CD80 and CD86 to levels observed with mRNA activation. DCs were activated with the indicated agents for 24 h followed by staining with directly conjugated specific antibodies and flow cytometrically analyzed. The mean fluorescence for each marker was calculated for each activation agent. P values were calculated by normalizing mean fluorescence based on the untreated samples from the three replicates and applying a one-tailed t test. A single-tailed t test was used as the predicted results of change for each activation marker was to only increase after activation. Error bars represent plus or minus two standard deviations.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the current report, we characterize a new signaling activity by extracellular mRNA that activates DC and determine the resulting phenotype and functional ability of mRNA-matured DC to activate T cells and compared it to other DC maturation stimuli. mRNA-activated DC expressed MHC classes I and II and coactivation molecules CD80 and CD86 at similar or greater levels than the potent DC activators, LPS, dsRNA, and CD40L. mRNA also induced IL-12, IFN-alpha , IL-8, and TNF-alpha production by DC. In vitro transcribed RNA containing a coding sequence extended with poly(A) tail and homopolymer poly(A) but not homopolymers made of U, C, or G, or mRNA lacking a poly(A) tail induced a calcium flux in DC. This Ca2+ flux was inhibited by pretreatment with ATP, ADP, pertussis toxin, and suramin, suggesting the involvement of a P2Y type, Gi-linked nucleotide receptor. Although poly(A) and mRNA lacking a poly(A) tail could induce some markers of DC activation, full maturation of DC, however, required mRNA that could induce TNF-alpha most likely by regions of dsRNA- and poly(A)-mediated signaling.

The data suggest that mRNA signals a Gi-protein-linked nucleotide receptor that can be desensitized by ATP and ADP. Two members of a new family of ADP P2Y receptors have recently been identified. This family demonstrates more homology to the UDP-glucose receptor than other members of the P2Y family, responds to concentrations of ADP 5- to 1000-fold lower than the respective ligands of other P2Y receptors, and generally inhibits adenylate cyclase production (29, 36, 42). The tissue distribution of P2Y12, platelets, and brain, and the ability of ATP to desensitize the poly(A) receptor suggest that P2Y12 and -13 receptors do not signal to mRNA, but as new members of this subclass of P2Y receptors are identified, they will need to be screened for DC expression and mRNA signaling.

Based on our data, we cannot determine whether mRNA uses a new nucleotide receptor present on DC but absent on other lymphoid cell types (T cells, B cells, monocyte/macrophages) or on cell lines constructed to express most known P2Y receptors or if mRNA is a ligand for a heterodimer of known GPCR. Heterodimers of GPCR have been observed in multiple systems, including chemokine (43), gamma -aminobutyric acid (44), opioid receptors (45, 46), and nucleotide receptors (P2Y) (47). The functional gamma -aminobutyric acid type B receptor is a heterodimer of two GPCR receptors with low homology to each other. The expression of both receptors is required for signal transduction following ligand binding (44). Thus, GPCR heterodimers can significantly change the binding affinity for ligands and form receptors capable of binding ligands to which neither receptor alone sends signal.

The ability of poly(A) to signal a GPCR on DC is highly suggestive that this signaling activity is responsible for the DC-activating properties we observed. We cannot exclude that poly(A) has another activity in addition to GPCR signaling. It is interesting that ATP and poly(A) both activate DC through GPCR but do so through different receptors and signaling mechanisms with different results. ATP signaling through P2Y11 increases cAMP concentrations in DC, a property shared with prostaglandin E2, another DC-activating agent that synergizes with TNF-alpha (48). This activation of cAMP leads to a reduced ability to secrete IL-12 (19, 23). Poly(A), whose signaling activity is likely due to an ADP family, P2Y type nucleotide receptor, does not increase cAMP levels and induces IL-12 secretion. A recent report highlighted the ability of ligands utilizing similar signal transduction pathways to differentially activate DC. In this report, signaling through TLR 2 and 4, which share signaling pathways, including NF-kappa B and mitogen-activated protein kinase family member activation, led to DC that differed in the cytokines produced and the resulting phenotype of T cells activated (13). A number of host cell-derived molecules cooperate with TNF-alpha , which by itself does not completely activate DC (49), to induce DC activation (18, 19, 23, 49-51). Some of these molecules (ATP, PGE2) alter the cytokine secretion patterns of the mature DC and the phenotype of the resulting T cells (18, 23, 51). We also observed that the addition of poly(A) to poly(I)·poly(C)-activated DC changed the resulting DC phenotype, such that it more closely resembled mRNA activation of DC compared with dsRNA. dsRNA has recently been demonstrated to signal TLR3 at concentrations at least 4-fold higher than that required for mRNA to induce DC activation (53). Further studies will be required to determine whether mRNA, containing a coding sequence, signals through TLR3. mRNA lacking a poly(A) tail induced markers of DC activation but at a level below that observed for mRNA with a poly(A) tail. The signaling by the poly(A) tail both increased the mRNA ability to mature DC and alter the phenotype of the activated DC.

These studies identify a new class of ligands for P2Y nucleotide receptors, mRNA. Originally described as a receptor that bound and induced a response to ATP, seven 7-transmembrane, G-protein linked nucleotide receptors have been identified in humans. Although nucleotide receptors are present on nearly every cell type, including immunologic, neurologic, cardiac, salivary, and bone, we have been unable to identify another cell type that fluxes Ca2+ in response to mRNA, suggesting the mRNA nucleotide receptor is restricted in its expression, as has been described for the members of a new family of ADP receptors, P2Y12 (36) and P2Y13 (29). In addition to nucleotide receptors, a class of receptors responsive to adenine dinucleotides has also been described (54). The ligand binding characteristics and the lack of sensitivity to inhibitors (pertussis toxin and suramin) of these receptors do not parallel those of poly(A)-mediated signaling. A number of orphan receptors related to nucleotide receptors have been identified. Studies are now in progress to identify whether an identified orphan or new nucleotide receptor, specific for poly(A) and mRNA containing a poly(A) tail, is present on DC or if receptor heterodimerization between known GPCR results in RNA signaling.

DCs obtain antigen from microbial pathogens through germ-line-encoded pattern recognition receptors. DCs are also responsible for developing immune responses to altered self where antigen loading occurs through the endocytosis and processing of infected or transformed cells. The use of mRNA to load DC with antigen as a vaccine has been observed to be an efficient and potent method for loading antigen-processing pathways for CD4+ T cells, CD8+ T cells (24, 25, 55-64), and B cells2 that exceeds those observed for DNA, viral, and protein immunization methods (52, 63-66). A hypothesis, that RNA may be used physiologically to load DC with antigen and activate them to induce immune responses to intracellularly infected and transformed self cells, can be forwarded. In this model, cell injury and non-apoptotic cell death releases mRNA that loads antigen-processing pathways and promotes DC activation. Support for this model includes the DC's superior ability to take up and translate extracellular mRNA (1000- to 10,000-fold better than other antigen presenting cell) (25), and the ability of mice injected with DC, pulsed with naked extracellular mRNA or immunized with RNA, to mount a primary immune response (25, 55). The finding of this report, that extracellular RNA has a specific signaling activity that potently activates DC, adds to this hypothesis.

    ACKNOWLEDGEMENT

We thank Dr. Skip Brass for the use of his fluorescence spectrophotometer.

    FOOTNOTES

* This work was supported by NHLBI, National Institutes of Health (NIH) Grant R01-HL-62060-1 and by NIAID, NIH Grant R21-AI-45318-01A1.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Division of Infectious Diseases, University of Pennsylvania, 522B Johnson Pavilion, Philadelphia, PA 19104. Tel.: 215-614-0291; Fax: 215-349-5111; E-mail: dreww@mail.med.upenn.edu.

Published, JBC Papers in Press, January 30, 2002, DOI 10.1074/jbc.M110729200

2 D. Weissman, G. Cannon, and K. Karikó, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: DC, dendritic cell(s); Treg, T regulatory; LPS, lipopolysaccharide; dsRNA, double-stranded RNA, CD40L, CD40 ligand; GPCR, G-protein-coupled receptor; ssDNA, single-stranded DNA; PE, phycoerythrin; FITC, fluorescein isothiocyanate; TLR, Toll-like receptor; PBMC, peripheral blood mononuclear cells; CPK, creatine phosphokinase; CP, creatine phosphate; MHC, major histocompatibility complex; IL-12, interleukin-12; IFN-alpha , interferon alpha ; TNF-alpha , tumor necrosis factor alpha ; FCS, fetal calf serum; HIV, human immunodeficiency virus; PGE2, prostaglandin E2; RANTES, regulated on activation normal T cell expressed and secreted; ELISA, enzyme-linked immunosorbent assay; 2MeSATP, 2-(methylthio)adenosine 5'-triphosphate; 2MeSADP, 2-(methylthio)adenosine 5'-diphosphate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Steinman, R. M., and Inaba, K. (1999) J. Leukoc. Biol. 66, 205-208[Abstract]
2. Steinman, R. M. (1991) Annu. Rev. Immunol. 9, 271-296[CrossRef][Medline] [Order article via Infotrieve]
3. Lanzavecchia, A. (1996) Curr. Opin. Immunol. 8, 348-354[CrossRef][Medline] [Order article via Infotrieve]
4. Imler, J. L., and Hoffmann, J. A. (2000) Rev. Immunogenet. 2, 294-304[Medline] [Order article via Infotrieve]
5. Pulendran, B., Palucka, K., and Banchereau, J. (2001) Science 293, 253-256[Abstract/Free Full Text]
6. Akira, S., Takeda, K., and Kaisho, T. (2001) Nat. Immunol. 2, 675-680[CrossRef][Medline] [Order article via Infotrieve]
7. Lanzavecchia, A., and Sallusto, F. (2001) Curr. Opin. Immunol. 13, 291-298[CrossRef][Medline] [Order article via Infotrieve]
8. Liu, Y. J., Kanzler, H., Soumelis, V., and Gilliet, M. (2001) Nat. Immunol. 2, 585-589[CrossRef][Medline] [Order article via Infotrieve]
9. Wan, Y., and Bramson, J. (2001) Curr. Pharm. Des. 7, 977-992[CrossRef][Medline] [Order article via Infotrieve]
10. Sallusto, F., and Lanzavecchia, A. (2000) Immunol. Rev. 177, 134-140[CrossRef][Medline] [Order article via Infotrieve]
11. Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S., and Mantovani, A. (2000) Immunol. Rev. 177, 141-149[CrossRef][Medline] [Order article via Infotrieve]
12. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I., and Lanzavecchia, A. (1999) J. Exp. Med. 189, 821-829[Abstract/Free Full Text]
13. Re, F., and Strominger, J. L. (2001) J. Biol. Chem. 276, 37692-37699[Abstract/Free Full Text]
14. Urban, B. C., Ferguson, D. J., Pain, A., Willcox, N., Plebanski, M., Austyn, J. M., and Roberts, D. J. (1999) Nature 400, 73-77[CrossRef][Medline] [Order article via Infotrieve]
15. Urban, B. C., Willcox, N., and Roberts, D. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8750-8755[Abstract/Free Full Text]
16. Ito, T., Amakawa, R., Inaba, M., Ikehara, S., Inaba, K., and Fukuhara, S. (2001) J. Immunol. 166, 2961-2969[Abstract/Free Full Text]
17. Berchtold, S., Ogilvie, A. L., Bogdan, C., Muhl-Zurbes, P., Ogilvie, A., Schuler, G., and Steinkasserer, A. (1999) FEBS Lett. 458, 424-428[CrossRef][Medline] [Order article via Infotrieve]
18. Schnurr, M., Then, F., Galambos, P., Scholz, C., Siegmund, B., Endres, S., and Eigler, A. (2000) J. Immunol. 165, 4704-4709[Abstract/Free Full Text]
19. Wilkin, F., Duhant, X., Bruyns, C., Suarez-Huerta, N., Boeynaems, J. M., and Robaye, B. (2001) J. Immunol. 166, 7172-7177[Abstract/Free Full Text]
20. Ferrari, D., La, Sala, A., Chiozzi, P., Morelli, A., Falzoni, S., Girolomoni, G., Idzko, M., Dichmann, S., Norgauer, J., and Di Virgilio, F. (2000) FASEB. J. 14, 2466-2476[Abstract/Free Full Text]
21. Mutini, C., Falzoni, S., Ferrari, D., Chiozzi, P., Morelli, A., Baricordi, O. R., Collo, G., Ricciardi-Castagnoli, P., and Di Virgilio, F. (1999) J. Immunol. 163, 1958-1965[Abstract/Free Full Text]
22. Coutinho-Silva, R., Perfettini, J. L., Persechini, P. M., Dautry-Varsat, A., and Ojcius, D. M. (2001) Am. J. Physiol. Cell. Physiol. 280, C81-C89[Abstract/Free Full Text]
23. la Sala, A., Ferrari, D., Corinti, S., Cavani, A., Di, Virgilio, F., and Girolomoni, G. (2001) J. Immunol. 166, 1611-1617[Abstract/Free Full Text]
24. Leitner, W. W., Ying, H., and Restifo, N. P. (1999) Vaccine 18, 765-777[CrossRef][Medline] [Order article via Infotrieve]
25. Weissman, D., Ni, H., Scales, D., Dude, A., Capodici, J., McGibney, K., Abdool, A., Isaacs, S. N., Cannon, G., and Kariko, K. (2000) J. Immunol. 165, 4710-4717[Abstract/Free Full Text]
26. Communi, D., Govaerts, C., Parmentier, M., and Boeynaems, J. M. (1997) J. Biol. Chem. 272, 31969-31973[Abstract/Free Full Text]
27. Kariko, K., Kuo, A., Barnathan, E. S., and Langer, D. J. (1998) Biochim. Biophys. Acta 1369, 320-334[Medline] [Order article via Infotrieve]
28. Communi, D., Motte, S., Boeynaems, J. M., and Pirotton, S. (1996) Eur. J. Pharmacol. 317, 383-389[CrossRef][Medline] [Order article via Infotrieve]
29. Communi, D., Suarez Gonzalez, N., Detheux, M., Brezillon, S., Lannoy, V., Parmentier, M., and Boeynaems, J. M. (2001) J. Biol. Chem. 276, 41479-41485[Abstract/Free Full Text]
30. Scales, D., Ni, H., Shaheen, F., Capodici, J., Cannon, G., and Weissman, D. (2001) J. Immunol. 166, 6437-6443[Abstract/Free Full Text]
31. Vissers, J. L., Hartgers, F. C., Lindhout, E., Teunissen, M. B., Figdor, C. G., and Adema, G. J. (2001) J. Leukoc. Biol. 69, 785-793[Abstract/Free Full Text]
32. Rissoan, M. C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R., and Liu, Y. J. (1999) Science 283, 1183-1186[Abstract/Free Full Text]
33. Otero, M., Garrad, R. C., Velazquez, B., Hernandez-Perez, M. G., Camden, J. M., Erb, L., Clarke, L. L., Turner, J. T., Weisman, G. A., and Gonzalez, F. A. (2000) Mol. Cell. Biochem. 205, 115-123[CrossRef][Medline] [Order article via Infotrieve]
34. Sabala, P., Czajkowski, R., Przybylek, K., Kalita, K., Kaczmarek, L., and Baranska, J. (2001) Br. J. Pharmacol. 132, 393-402[CrossRef][Medline] [Order article via Infotrieve]
35. Santiago-Perez, L. I., Flores, R. V., Santos-Berrios, C., Chorna, N. E., Krugh, B., Garrad, R. C., Erb, L., Weisman, G. A., and Gonzalez, F. A. (2001) J. Cell. Physiol. 187, 196-208[CrossRef][Medline] [Order article via Infotrieve]
36. Hollopeter, G., Jantzen, H. M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R. B., Nurden, P., Nurden, A., Julius, D., and Conley, P. B. (2001) Nature 409, 202-207[CrossRef][Medline] [Order article via Infotrieve]
37. Oppermann, M., Mack, M., Proudfoot, A. E., and Olbrich, H. (1999) J. Biol. Chem. 274, 8875-8885[Abstract/Free Full Text]
38. Luther, S. A., and Cyster, J. G. (2001) Nat. Immunol. 2, 102-107[CrossRef][Medline] [Order article via Infotrieve]
39. Communi, D., Janssens, R., Suarez-Huerta, N., Robaye, B., and Boeynaems, J. M. (2000) Cell. Signal 12, 351-360[CrossRef][Medline] [Order article via Infotrieve]
40. von Kugelgen, I., and Wetter, A. (2000) Naunyn-Schmiedeberg's Arch. Pharmacol. 362, 310-323[CrossRef][Medline] [Order article via Infotrieve]
41. Di Virgilio, F., Chiozzi, P., Ferrari, D., Falzoni, S., Sanz, J. M., Morelli, A., Torboli, M., Bolognesi, G., and Baricordi, O. R. (2001) Blood. 97, 587-600[Abstract/Free Full Text]
42. Zhang, F. L., Luo, L., Gustafson, E., Lachowicz, J., Smith, M., Qiao, X., Liu, Y. H., Chen, G., Pramanik, B., Laz, T. M., Palmer, K., Bayne, M., and Monsma, F. J., Jr. (2001) J. Biol. Chem. 276, 8608-8615[Abstract/Free Full Text]
43. Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., Fernandez, S., Martin de Ana, A., Jones, D. R., Toran, J. L., and Martinez, A. C. (2001) EMBO J. 20, 2497-2507[CrossRef][Medline] [Order article via Infotrieve]
44. Jones, K. A., Tamm, J. A., Craig, D. A., Ph, D., Yao, W., and Panico, R. (2000) Neuropsychopharmacology 23, S41-S49[CrossRef][Medline] [Order article via Infotrieve]
45. Jordan, B. A., and Devi, L. A. (1999) Nature 399, 697-700[CrossRef][Medline] [Order article via Infotrieve]
46. Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000) J. Neurosci. 20, RC110[Abstract/Free Full Text]
47. Yoshioka, K., Saitoh, O., and Nakata, H. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7617-7622[Abstract/Free Full Text]
48. Rieser, C., Bock, G., Klocker, H., Bartsch, G., and Thurnher, M. (1997) J. Exp. Med. 186, 1603-1608[Abstract/Free Full Text]
49. Granucci, F., Vizzardelli, C., Virzi, E., Rescigno, M., and Ricciardi-Castagnoli, P. (2001) Eur. J. Immunol. 31, 2539-2546[CrossRef][Medline] [Order article via Infotrieve]
50. Delneste, Y., Herbault, N., Galea, B., Magistrelli, G., Bazin, I., Bonnefoy, J. Y., and Jeannin, P. (1999) J. Immunol. 163, 3071-3075[Abstract/Free Full Text]
51. Steinbrink, K., Paragnik, L., Jonuleit, H., Tuting, T., Knop, J., and Enk, A. H. (2000) Arch. Dermatol. Res. 292, 437-445[CrossRef][Medline] [Order article via Infotrieve]
52. Morse, M. A., Lyerly, H. K., Gilboa, E., Thomas, E., and Nair, S. K. (1998) Cancer Res. 58, 2965-2968[Abstract/Free Full Text]
53. Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001) Nature 413, 732-738[CrossRef][Medline] [Order article via Infotrieve]
54. Pintor, J., and Miras-Portugal, M. T. (1995) Br. J. Pharmacol. 115, 895-902[Medline] [Order article via Infotrieve]
55. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., and Gilboa, E. (1998) Nat. Biotechnol. 16, 364-369[CrossRef][Medline] [Order article via Infotrieve]
56. Gilboa, E., Nair, S. K., and Lyerly, H. K. (1998) Cancer. Immunol. Immunother. 46, 82-87[CrossRef][Medline] [Order article via Infotrieve]
57. Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., and Gilboa, E. (1997) J. Exp. Med. 186, 1177-1182[Abstract/Free Full Text]
58. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. (1996) J. Exp. Med. 184, 465-472[Abstract/Free Full Text]
59. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. (1999) Prostate 39, 54-59[CrossRef][Medline] [Order article via Infotrieve]
60. Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S., Vieweg, J., and Gilboa, E. (2000) Nat. Med. 6, 1011-1017[CrossRef][Medline] [Order article via Infotrieve]
61. Ying, H., Zaks, T. Z., Wang, R. F., Irvine, K. R., Kammula, U. S., Marincola, F. M., Leitner, W. W., and Restifo, N. P. (1999) Nat. Med. 5, 823-827[CrossRef][Medline] [Order article via Infotrieve]
62. Zhang, W., He, L., Yuan, Z., Xie, Z., Wang, J., Hamada, H., and Cao, X. (1999) Hum. Gene. Ther. 10, 1151-1161[CrossRef][Medline] [Order article via Infotrieve]
63. Van Tendeloo, V. F., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., and Berneman, Z. N. (2001) Blood 98, 49-56[Abstract/Free Full Text]
64. Strobel, I., Berchtold, S., Gotze, A., Schulze, U., Schuler, G., and Steinkasserer, A. (2000) Gene. Ther. 7, 2028-2035[CrossRef][Medline] [Order article via Infotrieve]
65. Saenz-Badillos, J., Amin, S. P., and Granstein, R. D. (2001) Exp. Dermatol. 10, 143-154[CrossRef][Medline] [Order article via Infotrieve]
66. Andersson, C., Vasconcelos, N. M., Sievertzon, M., Haddad, D., Liljeqvist, S., Berglund, P., Liljestrom, P., Ahlborg, N., Stahl, S., and Berzins, K. (2001) Scand J. Immunol. 54, 117-124[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Lichtnekert, V. Vielhauer, D. Zecher, O. P. Kulkarni, S. Clauss, S. Segerer, V. Hornung, T. N. Mayadas, B. Beutler, S. Akira, et al.
Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif
Am J Physiol Renal Physiol, April 1, 2009; 296(4): F867 - F874.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
U. Koedel, U. M. Merbt, C. Schmidt, B. Angele, B. Popp, H. Wagner, H.-W. Pfister, and C. J. Kirschning
Acute Brain Injury Triggers MyD88-Dependent, TLR2/4-Independent Inflammatory Responses
Am. J. Pathol., July 1, 2007; 171(1): 200 - 213.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. Marteau, D. Communi, J.-M. Boeynaems, and N. Suarez Gonzalez
Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells
J. Leukoc. Biol., October 1, 2004; 76(4): 796 - 803.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Kariko, H. Ni, J. Capodici, M. Lamphier, and D. Weissman
mRNA Is an Endogenous Ligand for Toll-like Receptor 3
J. Biol. Chem., March 26, 2004; 279(13): 12542 - 12550.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Marteau, E. Le Poul, D. Communi, D. Communi, C. Labouret, P. Savi, J.-M. Boeynaems, and N. S. Gonzalez
Pharmacological Characterization of the Human P2Y13 Receptor
Mol. Pharmacol., July 1, 2003; 64(1): 104 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Su, J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg
Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA-transfected Dendritic Cells
Cancer Res., May 1, 2003; 63(9): 2127 - 2133.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/15/12689    most recent
M110729200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ni, H.
Right arrow Articles by Weissman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ni, H.
Right arrow Articles by Weissman, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement